Featured Research

from universities, journals, and other organizations

Drugs that flush out HIV may impair killer T cells, possibly hindering HIV eradication

Date:
August 14, 2014
Source:
PLOS
Summary:
Histone deacetylase (HDAC) inhibitors have shown promise in 'flushing out' HIV from latently infected cells, potentially exposing the reservoirs available for elimination by cytotoxic T lymphocytes (CTL), also called killer T cells. However, findings now suggest that treatment with HDAC inhibitors might suppress CTL activity and therefore compromise the 'kill' part of a two-pronged 'flush-and-kill' HIV eradication strategy.

Histone deacetylase (HDAC) inhibitors have shown promise in "flushing out" HIV from latently infected cells, potentially exposing the reservoirs available for elimination by cytotoxic T lymphocytes (CTL), also called killer T cells. However, findings published on August 14th in PLOS Pathogens now suggest that treatment with HDAC inhibitors might suppress CTL activity and therefore compromise the "kill" part of a two-pronged "flush-and-kill" HIV eradication strategy.

At least three different HDAC inhibitors, romidepsin, panobinostat, and SAHA, are under investigation as flushing agents. The individual drugs differ somewhat in their specificity for the 18 known human HDACs, and are also known to interact with other cellular factors and to alter the function of immune cells. Arguing that "this high degree of complexity both in terms of immunological outcomes and underlying mechanisms, necessitates that HDAC inhibitors be studied in a context that is matched to their intended utility," Brad Jones, from the Ragon Institute of Massachusetts General Hospital, Massachusetts Institute of Technology and Harvard, Boston, USA, and colleagues set out to test whether the three drugs affected the ability of CTL to eliminate HIV-infected target cells.

While the individual effects of the drugs on virus-specific CTL differ somewhat depending on specific assays, schedules, and doses, treatment with any of the three HDAC inhibitors impaired the ability of CTL to kill HIV-infected immune cells. All three drugs also rapidly suppressed CTL production of the key immune mediator interferon gamma.

Discussing the limitations of the study, the researchers state that, because their assays all involve drug treatment of CTL in cell culture settings, the extent to which HDAC inhibitors impact CTL function in HIV infected patients remains unknown. Consequently, they hope that their results will "motivate the incorporation of assays measuring ex-vivo T-cell function into ongoing and planned clinical trials of HDAC inhibitors, and that immunosuppression will be considered as a potential factor limiting the effectiveness of any observed outcomes." They also highlight the potential broader risk of treating HIV-positive individuals -- whose immune systems remain compromised even on antiretroviral therapy -- with HDAC inhibitors that have shown immunosuppressive activity in several studies, including this one.


Story Source:

The above story is based on materials provided by PLOS. Note: Materials may be edited for content and length.


Journal Reference:

  1. Richard Brad Jones, Rachel O'Connor, Stefanie Mueller, Maria Foley, Gregory L. Szeto, Dan Karel, Mathias Lichterfeld, Colin Kovacs, Mario A. Ostrowski, Alicja Trocha, Darrell J. Irvine, Bruce D. Walker. Histone Deacetylase Inhibitors Impair the Elimination of HIV-Infected Cells by Cytotoxic T-Lymphocytes. PLoS Pathogens, 2014; 10 (8): e1004287 DOI: 10.1371/journal.ppat.1004287

Cite This Page:

PLOS. "Drugs that flush out HIV may impair killer T cells, possibly hindering HIV eradication." ScienceDaily. ScienceDaily, 14 August 2014. <www.sciencedaily.com/releases/2014/08/140814191945.htm>.
PLOS. (2014, August 14). Drugs that flush out HIV may impair killer T cells, possibly hindering HIV eradication. ScienceDaily. Retrieved September 18, 2014 from www.sciencedaily.com/releases/2014/08/140814191945.htm
PLOS. "Drugs that flush out HIV may impair killer T cells, possibly hindering HIV eradication." ScienceDaily. www.sciencedaily.com/releases/2014/08/140814191945.htm (accessed September 18, 2014).

Share This



More Health & Medicine News

Thursday, September 18, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

The Cost of Ebola

The Cost of Ebola

Reuters - Business Video Online (Sep. 18, 2014) As Sierra Leone prepares for a three-day "lockdown" in its latest bid to stem the spread of Ebola, Ciara Lee looks at the financial implications of fighting the largest ever outbreak of the disease. Video provided by Reuters
Powered by NewsLook.com
What HealthKit Bug Means For Your iOS Fitness Apps

What HealthKit Bug Means For Your iOS Fitness Apps

Newsy (Sep. 18, 2014) Apple has delayed the launch of the HealthKit app platform, citing a bug. Video provided by Newsy
Powered by NewsLook.com
Residents Vaccinated as Haiti Fights Cholera Epidemic

Residents Vaccinated as Haiti Fights Cholera Epidemic

AFP (Sep. 18, 2014) Haitians receive the second dose of the vaccine against cholera as part of the UN's vaccination campaign. Duration: 00:34 Video provided by AFP
Powered by NewsLook.com
Raw: Elephant Undergoes Surgery in Tbilisi Zoo

Raw: Elephant Undergoes Surgery in Tbilisi Zoo

AP (Sep. 18, 2014) Grand the elephant has successfully undergone surgery to remove a portion of infected tusk at Tbilisi Zoo in Georgia. British veterinary surgeons used an electric drill to extract the infected piece. (Sept. 18) Video provided by AP
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins